Status:

WITHDRAWN

Determinants in Antidepressant Outcomes

Lead Sponsor:

US Department of Veterans Affairs

Conditions:

Depression

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study is designed to understand if a biological measurement, of how platelets respond to serotonin (a chemical in the blood sometimes referred to as SERT), can provide information that will deter...

Detailed Description

OBJECTIVE: The objective of this dose-ranging three-arm study of fluoxetine is to study the kinetics of the serotonin transporter in platelets and relate this to antidepressant response by comparing t...

Eligibility Criteria

Inclusion

  • A current episode satisfying DSM-IV criteria for Major Depressive Disorder (except controls).
  • No psychotropic medication during the previous 2 weeks before baseline (no SSRIs or SNRIs for previous 3 months).
  • A current depression score of 20 or greater on the 24-item Hamilton Depression Scale (patients).
  • Willingness and ability to give informed consent.
  • Age 18 and up.

Exclusion

  • Cardiovascular disease; subjects w/ myocardial infarcts within the past 3 months, heart failure, or other evidence of compromised cardiac function
  • Uncontrolled hypertension: systolic blood pressure \> 160, or diastolic \> 95
  • Previously noted thyroid disease, unless clinically euthyroid for 2 or more months.
  • Endocrine disease or exogenous hormones except HRT for postmenopausal women.
  • Women not using an effective method of birth control (barrier method, oral contraceptives and/or IUD), pregnant or lactating women.
  • Women with menometrorrhagia, premenstrual dysphoric disorder (PMDD), or premenopausal hysterectomized women with intact ovaries, or without HRT.
  • Subjects who require concomitant psychotropic medications. Psychotropic medication during the previous 2 weeks before baseline, 3 months for SSRIs or SNRIs, or 4 months for depot neuroleptics.
  • Evidence of clinically significant gastrointestinal, hepatic, renal, endocrine, ophthalmologic, neurologic, cardiovascular or hematological disease including anemia, hemophilia, or significant liver disease.
  • History of intolerable side effects to the proposed treatment.
  • Patients who have ever met DSM-IV criteria for any psychosis, schizophrenia, bipolar disorder, organic brain syndrome or any other primary Axis I major psychiatric disorder other than major depression. Controls must be without past history of depression.
  • Patients who meet DSM-IV criteria for any substance abuse during the past 2 months or dependence during the last 6 months, including positive urine drug screens.
  • History of priapism
  • Subjects who are starting a new psychotherapy program during the 16 weeks of study.

Key Trial Info

Start Date :

January 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2005

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00108316

Start Date

January 1 2004

End Date

September 1 2005

Last Update

September 27 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

VA Medical Center, Augusta

Augusta, Georgia, United States, 30904

Determinants in Antidepressant Outcomes | DecenTrialz